A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.

Nathan Heitz Samuel C Greer Zachery Halford

Published in: The Annals of pharmacotherapy (2022)

TV is the first Food and Drug Administration-approved TF-directed ADC. With a manageable safety profile and promising anticancer activity, TV warrants consideration as a novel targeted agent for the treatment of recurrent or metastatic cervical cancer. Further studies are required to determine the optimal place in therapy for TV.

Keyphrases

drug administration
squamous cell carcinoma
small cell lung cancer
cancer therapy
magnetic resonance imaging
hodgkin lymphoma
diffusion weighted
combination therapy
risk assessment
drug delivery
replacement therapy